RecruitingPhase 4NCT05799105

OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers

OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers After Bariatric Surgery


Sponsor

Stephen Firkins

Enrollment

122 participants

Start Date

Mar 14, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to identify the most effective way to take acid-blocking medications to treat stomach ulcers in patients who have undergone gastric bypass surgery. The main questions it aims to answer are: * is taking an acid-blocking medication by opening the capsule and only taking the contents of the capsule (open-capsule) more or less effective than taking the capsule as a whole (intact-capsule) for treating ulcers in patients who have a history of gastric bypass surgery? * does taking the open versus intact medication decrease the number of procedures and complications from untreated ulcers? Participants with ulcers will be instructed to take acid-blocking medications (called proton-pump inhibitors) either by opening the capsule and taking only the contents or by taking the capsule whole. These medications are the gold standard for treatment of stomach ulcers. Participants will be asked to undergo an upper endoscopy (EGD) every 3 months to monitor the healing of the ulcers. Researchers will compare how quickly the ulcers heal depending on which way the medications are taken (opened up or as a whole).


Eligibility

Inclusion Criteria1

  • Subjects diagnosed with marginal ulceration post-gastric bypass on upper endoscopy

Exclusion Criteria1

  • Refusal to start PPI medication OR current open-capsule PPI use at the time of diagnosis of the marginal ulcer

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOmeprazole 40 milligrams

Subjects will be randomized to treatment with either open-capsule or intact-capsule omeprazole to assess effect on ulcer healing times. If interim analysis illustrates significantly improved healing in the open-capsule group, the control (intact-capsule) arm will be allowed to cross-over to open-capsule and be followed until confirmed ulcer healing.


Locations(1)

Cleveland Clinic Foundation

Cleveland, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05799105


Related Trials